Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease

Abstract Objectives: We examined florbetapir positron emission tomography (PET) amyloid scans across stages of preclinical Alzheimer’s disease (AD) in cortical, allocortical, and subcortical regions. Stages were characterized using empirically defined methods. Methods: A total of 312 cognitively normal Alzheimer’s Disease Neuroimaging Initiative participants completed a neuropsychological assessment and florbetapir PET scan. Participants were classified into stages of preclinical AD using (1) a novel approach based on the number of abnormal biomarkers/cognitive markers each individual possessed, and (2) National Institute on Aging and the Alzheimer’s Association (NIA-AA) criteria. Preclinical AD groups were compared to one another and to a mild cognitive impairment (MCI) sample on florbetapir standardized uptake value ratios (SUVRs) in cortical and allocortical/subcortical regions of interest (ROIs). Results: Amyloid deposition increased across stages of preclinical AD in all cortical ROIs, with SUVRs in the later stages reaching levels seen in MCI. Several subcortical areas showed a pattern of results similar to the cortical regions; however, SUVRs in the hippocampus, pallidum, and thalamus largely did not differ across stages of preclinical AD. Conclusions: Substantial amyloid accumulation in cortical areas has already occurred before one meets criteria for a clinical diagnosis. Potential explanations for the unexpected pattern of results in some allocortical/subcortical ROIs include lack of correspondence between (1) cerebrospinal fluid and florbetapir PET measures of amyloid, or between (2) subcortical florbetapir PET SUVRs and underlying neuropathology. Findings support the utility of our novel method for staging preclinical AD. By combining imaging biomarkers with detailed cognitive assessment to better characterize preclinical AD, we can advance our understanding of who is at risk for future progression. (JINS, 2016, 22, 978–990)

[1]  D. Salmon,et al.  Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. , 2014, Journal of Alzheimer's disease : JAD.

[2]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[3]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[4]  Keith A. Johnson,et al.  The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.

[5]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[6]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[7]  M. Bondi,et al.  Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype. , 2016, Journal of Alzheimer's disease : JAD.

[8]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[9]  D. Delis,et al.  Quantification of five neuropsychological approaches to defining mild cognitive impairment. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[10]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[11]  H. Braak,et al.  Alzheimer's Disease: Striatal Amyloid Deposits and Neurofibrillary Changes , 1990, Journal of neuropathology and experimental neurology.

[12]  Majaz Moonis,et al.  Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.

[13]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[14]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[15]  Christos Davatzikos,et al.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings , 2013, Acta Neuropathologica Communications.

[16]  Pedro Rosa-Neto,et al.  Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[17]  C. Jack,et al.  Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. , 2015, JAMA neurology.

[18]  Tilo Kircher,et al.  Accuracy and Reliability of Automated Gray Matter Segmentation Pathways on Real and Simulated Structural Magnetic Resonance Images of the Human Brain , 2012, PloS one.

[19]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[20]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[21]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[22]  Sakari Savolainen,et al.  Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. , 2008, Archives of neurology.

[23]  D. Salmon,et al.  Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[24]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[25]  Douglas G Altman,et al.  Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.

[26]  D. Salmon,et al.  "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. , 2016, Journal of Alzheimer's disease : JAD.

[27]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[28]  Meghan B. Mitchell,et al.  A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery , 2011, Alzheimer's Research & Therapy.

[29]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[30]  Panteleimon Giannakopoulos,et al.  Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts , 1997, Brain Research Reviews.

[31]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[32]  Sang Won Seo,et al.  Amyloid deposition in early onset versus late onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[33]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[34]  K. Ishii,et al.  Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology. , 2015, Current Alzheimer research.

[35]  Christos Davatzikos,et al.  Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition , 2014, Acta neuropathologica communications.

[36]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[37]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[38]  Nathaniel Mercaldo,et al.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.

[39]  L. Wilkins Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2017, Neurology.

[40]  R. Petersen Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[41]  R. Elble,et al.  The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. , 1997, Neuropathology and applied neurobiology.

[42]  J. Schneider,et al.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.

[43]  M. Bondi,et al.  Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors , 2015, Alzheimer's & Dementia.

[44]  Francis Eustache,et al.  Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.

[45]  Denise C. Park,et al.  &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.

[46]  H. Braak,et al.  The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. , 2015, Brain : a journal of neurology.

[47]  K. Blennow,et al.  Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid , 2013, Acta Neuropathologica.

[48]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[49]  D. Salmon,et al.  Are Empirically-Derived Subtypes of Mild Cognitive Impairment Consistent with Conventional Subtypes? , 2013, Journal of the International Neuropsychological Society.

[50]  M. Bondi,et al.  Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria , 2016, Neurology.

[51]  C. Buckley,et al.  Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. , 2016, Journal of Alzheimer's disease : JAD.

[52]  R. Brookmeyer,et al.  Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia , 2012, Neurology.

[53]  F. Schmitt,et al.  Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.

[54]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[55]  Rodger J. Elble,et al.  The distribution of amyloid β protein deposition in the corpus striatum of patients with Alzheimer's disease , 1997 .

[56]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[57]  A. Hirano,et al.  Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease , 2004, Acta Neuropathologica.

[58]  Owen Carmichael,et al.  Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. , 2013, Psychology and aging.

[59]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.